Predicting survival in light chain amyloidosis.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

10 citing papers in PubMed.

1. Characterization, outcome and identification of prognostic factors for patients with systemic immunoglobulin lightchain amyloidosis requiring dialysis prior to initial anticlonal therapy.Haematologica · 2025
   Article
2. Predicting prognosis of light-chain cardiac amyloidosis by magnetic resonance imaging and deep learning.European heart journal. Cardiovascular Imaging · 2025
   Article
3. Clonal hematopoiesis of indeterminate potential in patients with immunoglobulin light-chain AL amyloidosis.Blood advances · 2024
   Article
4. Light-Chain Amyloidosis: The Great Impostor.Life (Basel, Switzerland) · 2023
   Review
5. Pomolidomide for relapsed/refractory light chain amyloidosis after resistance to both bortezomib and daratumumab: A case report.World journal of clinical cases · 2022
   Article
6. The diagnostic value of multiparameter cardiovascular magnetic resonance for early detection of light-chain amyloidosis from hypertrophic cardiomyopathy patients.Frontiers in cardiovascular medicine · 2022
   Article
7. Real world data on light chain cardiac amyloidosis: Still a delayed diagnosis.Frontiers in oncology · 2022
   Article
8. Current Updates on the Management of AL Amyloidosis.Journal of hematology · 2021
   Review
9. Updates in the Diagnosis and Management of AL Amyloidosis.Current hematologic malignancy reports · 2020
   Review
10. Clinical characterization and outcomes of a cohort of colombian patients with AL Amyloidosis.Colombia medica (Cali, Colombia)
    Article

Corrections and comments

• Comment on
  Performance analysis of AL amyloidosis cardiac biomarker staging systems with special focus on renal failure and atrial arrhythmia.2019

Authors and funding

3 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as